CAR T-cell vs bispecific antibodies in relapsed/refractory mantle cell lymphoma: a systematic review and meta-analysis.

What was studied

This was a systematic review and meta-analysis. It compared CAR T-cell therapy with bispecific drugs. This was in mantle cell lymphoma that had relapsed or resisted treatment. All patients were in third-line care or later. The authors searched large databases up to October 2024. They pooled response rates and serious adverse events. They say no study had compared these treatments before.

What they found

The review included 237 patients. Complete response rates were 0.63 for the bispecific drugs. They were 0.70 for CAR T-cell therapy. Overall response rates were close, at 0.75 versus 0.88. Cytokine release syndrome of grade 3 or worse was equal, at 0.06 each. Nerve toxic effects could not be compared.

What it means for patients

The authors say CAR T-cell therapy had higher complete response rates than the bispecific drugs. They say the results support these treatments as effective third-line options.

Why it is not certain yet

The review had only a few studies. Treatments were not tested head to head in one trial. The authors say randomised trials are needed to confirm the findings. The abstract says nerve toxic effects could not be compared.

Source

CAR T-cell vs bispecific antibodies in relapsed/refractory mantle cell lymphoma: a systematic review and meta-analysis.

We restate facts from the source record in our own words. The original wording belongs to its publisher.